Tumor cell migration is mediated by cell-autonomous signaling mechanisms as well as paracrine and autocrine factors secreted by activated stromal cells in the tumor microenvironment. Like other members of the ADAM (a disintegrin and metalloproteinase) family, the integrin-binding metalloproteinase ADAM9 modulates cell-cell and cell-matrix interactions as well as ectodomain shedding of cell surface receptors and ligands, thereby modifying intracellular and extracellular signaling. ADAM9 transcripts are alternatively spliced to express a transmembrane protein (ADAM9-L) and a secreted variant (ADAM9-S). In this study, we show that ADAM9-S promotes breast cancer cell migration in a manner requiring its metalloproteinase activity, whereas ADAM9-L suppresses cell migration independent of its metalloproteinase activity. Suppression of migration by ADAM9-L requires a functional disintegrin domain and integrin binding. Expression analysis revealed that both ADAM9 isoforms are expressed in breast cancer cell lines and tissues. Therefore, relative levels of membrane-tethered and secreted variants of ADAM9 are a key determinant in manifestation of aggressive migratory phenotypes associated with breast cancer progression.
Introduction
One of the hallmarks of advanced breast cancer is the ability of the tumor cells to lose their epithelial phenotype, disengage from neighboring cells, degrade the basement membrane, and invade surrounding tissues, ultimately metastasizing to distant organs. The interactions between the tumor and its stromal microenvironment are a key determinant in breast cancer progression from carcinoma in situ to advanced invasive and metastatic carcinoma. Tumor cells proteolyze the basement membrane and stroma to invade the vasculature, and also alter stromal signals to stimulate angiogenesis and alternately release and tether to the extracellular matrix (ECM) to allow for efficient migration. Tumor cells also release growth factors and chemokines that alter the stroma, inducing inflammation, angiogenesis, and mechanisms of tissue repair (1, 2) .
Proteases play a major signaling role at the tumor-stromal boundary. Enzymes comprising the matrix metalloproteinase (MMP) family proteolyze basement membrane and function in promigratory signaling mechanisms. Proteolysis by MMPs exposes cryptic sites in ECM constituents such as laminin-5 and collagen IV that in turn promote tumor cell migration (3, 4) . Proteolysis of the basement membrane also releases ECM-bound growth factors such as insulin and fibroblast growth factor (5, 6) . MMPs proteolytically cleave and release the ectodomains of multiple signaling molecules from the cell membrane in a process known as membrane shedding (7) . Shedding of substrates such as transforming growth factor-β (8) and tumor necrosis factor-α (9) activates signaling pathways that promote cell migration and survival. The ADAM (a disintegrin and metalloproteinase) family of proteases has functional similarity to the MMPs in their zinc-binding metalloproteinase domains, and is also referred to as the metalloproteinase, disintegrin, cysteine-rich (MDC) family. ADAMs control basement membrane proteolysis and shedding of proteins from the cell membrane. Comprising 40 isoforms, the ADAM family of proteases also contains an integrin-binding disintegrin domain. ADAMs function in cell adhesion through their cysteinerich domains that bind to syndecans (10) and fibronectin (11) . The Src homology-3 (SH3)-binding domain in the cytoplasmic regions of some ADAMs mediates signaling by activation of Src and Grb proteins (12) . Recent studies point to a functional importance for some ADAM family members in cancer. ADAM12 is expressed in carcinoma and promotes breast cancer progression by inducing the apoptosis of surrounding stromal cells (13) . Consequently, ADAM12 protein levels correlate with advanced breast cancer (14, 15) . In contrast, the disintegrin domain of ADAM15 inhibits angiogenesis and tumor growth (16) . Moreover, ADAM15 expression decreases integrin-mediated ovarian cancer cell adhesion and motility (17) .
ADAM9, also known as MDC9 (metalloproteinase/disintegrin/ cysteine-rich protein 9), MCMP (myeloma cell metalloproteinase), and meltrin-γ, comprises a subgroup of ADAMs that also contains ADAM12 and ADAM15 (18) . The ADAM9 metalloproteinase activity cleaves heparin-binding epidermal growth factor (EGF; ref. 19) , which binds activates EGF receptor to promote tumor growth and angiogenesis (20) . ADAM9 also cleaves Delta-like 1, a Notch ligand (21) , as well as ADAM10 (22, 23) . The ADAM9 disintegrin domain is a ligand for specific integrin heterodimers, including multiple β 1 (24, 25) , α 6 β 4 (26) , and α v β 5 integrins (27, 28) .
Recent studies have revealed that ADAM9 message is upregulated in breast tumors as well as in breast cancer cell lines (29, 30) . The chromosomal region of the ADAM9 gene (8p11-12) is amplified in several breast cancers and cell lines, and ADAM9 is overexpressed in cell lines encompassing the luminal, basal A, and basal B gene expression clusters (31) .
The ADAM9 transcript is alternatively spliced into membranebound and secreted isoforms. Alternative splicing of exon 12 in the ADAM9 message leads to a shorter ADAM9-S (ADAM9-secreted) transcript that contains eight unique amino acids not present in ADAM9-L (ADAM9-long). ADAM9-S also lacks the transmembrane and cytoplasmic domains and is a secreted protein (26) . ADAM9 is implicated in cancer cell phenotypes, as secretion of ADAM9-S promotes invasion of breast cancer cells in Matrigel assays (26) . Furthermore, adhesion of keratinocyte cells to recombinant ADAM9 disintegrin/cysteine-rich domain increases cell migration, and overexpression of ADAM9 also increases pro-MMP9 expression (25) . However, the functional role of ADAM9-L and ADAM9-S in modulating cell migration and invasion in breast cancer cells has not been evaluated.
Here, we use specific ADAM9-L and ADAM9-S antibodies to detect expression of both variants in breast cancer cell lines and breast cancer tissues. Using RNA interference (RNAi) and gene replacement, we show that ADAM9-S and ADAM9-L do not function in a redundant manner in the regulation of cell migration, whereby ADAM9-S promotes and ADAM9-L attenuates migration. These studies identify for the first time an ADAM as a migration suppressor, and have implications for the functional roles of ADAM9 proteins in breast cancer progression.
Materials and Methods

Antibodies and reagents
Anti-myc antibody purified from the 9B11 hybridoma was purchased from Cell Signaling Technology. Anti-β-actin was from Sigma-Aldrich. Anti-ADAM9-L was from BioMol Research Laboratories, Inc. Anti-ADAM9-S was designed and produced in collaboration with Pro-Sci, Inc. as a rabbit polyclonal antibody based on the immunization peptide sequence CATGLSLKFHAPF. Transient transfections were performed with Lipofectamine 2000 (Invitrogen) or polyethyleimine (Polysciences, Inc). pcDNA3-mA9L, pcDNA3-mA9L.EA, pcDNA3-mADAM9L.myc, and pcDNA4-hADAM9S.myc have been described previously (12, 26) . Point mutants mADAM9L. EA.myc, ADAM9S.EA.myc, and ADAM9L.TCE.myc were derived from these vectors via Stratagene site-directed mutagenesis according to the manufacturer's instructions and the following primers: ADAM9S.EA, 5′-CCAAGATTATGACCCAATG-C A T G A G C A AC A A T G G -3 ′ a n d 5 ′ -CC A T T G T T G C T-CATGCATTGGGTCATAATCTTGG-3′; mADAM9L.EA, 5′-CCATTGTTGCTCATGCATTGGGGCATAACCTTGG-3′ and 5′-CCAAGGTTATGCCCCAATGCATGAGCAACAATGG-3′; mADAM9L.TCE.myc, 5′-GGACCCTGGAGAGCGTGT-GAATGCGGC-3′ and 5′-GCCGCATTCACACGTCTCTC-CAGGGTCC-3′. Deletion mutations in mADAM9L.Δcyt.myc and mADAM9L.Δdis.myc were derived as follows: To delete the cytoplasmic domain, a Kpn1 restriction site was inserted into pcDNA3-mADAM9-L 5′ of the cytoplasmic region with primers 5′-GGCTAACTAGAGAACCCACTGGTACCTG-GCTTATCG-3′ and 5′-CGATAAGCCAGGTACCAGTG-GGTTCTCTAGTTAGCC-3′. BamHI from the vector backbone and the inserted Kpn1 restriction sites were used to isolate the mADAM9L.Δcyt sequence, which was cloned into digested pcDNA4A/TO/myc/his vector in frame with the myc tag. To delete the disintegrin domain, Kpn1 sites were inserted 5′ and 3′ of the disintegrin domain in pcDNA3-mADAM9L.myc using sitedirected mutagenesis using the following sequences: 5′ Kpn1, 5′-GTGGAGCAAAGAGCGGTACCATGAATTCAGGAGC-3′ and 5′-GCTCCTGAATTCATGGTACCGCTCTTTGCTCCAC-3′; 3′ Kpn1, 5′-GAAGGAGTGTGAGGGTACCCCATGCTGTGAAG-GAAG-3′ and 5′-CTTCCTTCACAGCATGGGGTACCCTCA-CACTCCTTC-3′. Kpn1 digestion was used to isolate and discard the disintegrin sequence, and the vector backbone Kpn1 sites were ligated. For RNAi, ADAM9 sequences from the Mission small interfering RNA (siRNA) project (SigmaAldrich) were cloned into the pLKO.1 vector directing expression of short hairpin RNA (shRNA; ref. 32). The following sequences were used: ADAM9shRNA.
1, 5′-CCGGCCCAGAGAAGTT-C C T A T A T A T C T C G A G A T A T A T A G G A A C T T C T -
CTGGGTTTTTG-3′ (sense) and 5′-AATTCAAAAACCCAGA-GAAGTTCCTATATATCTCGAGATATATAGGAACTTCTCTGG-3′ (antisense); ADAM9shRNA.2, 5′-CCGGGCCAGAATAA-CAAAGCCTATTCTCGAGAATAGGCTTTGTTATTCTGGCTTT-3′ (sense) and 5′-AATTCAAAAAGCCAGAATAACAAAGCC-TATTCTCGAGAATAGGCTTTGTTATTCTGGC-3′ (antisense). Second-generation lentiviral packaging plasmids pCMV-dR8.2 dvpr and pCMV-VSVG were obtained from Addgene for lentiviral packaging.
Cell lines
All cell lines were obtained from the American Type Culture Collection, with the exception of the estrogen-independent human breast cancer SUM-159-PT, which has been described (33) . BT549, HCC38, and ZR75-1 cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum. MDA-MB-231, HEK293T, MDA-MB-468, and NIH3T3 cells were maintained in DMEM supplemented with 10% fetal bovine serum. CAMA-1 cells were maintained in MEM supplemented with 10% fetal bovine serum. SKBR3 cells were maintained in McCoy's modified medium 5A supplemented with 10% fetal bovine serum. MCF10A cells were maintained in DMEM modified with 5% equine serum, 20 ng/mL EGF, 10 μg/mL insulin, 100 ng/mL cholera toxin, 500 ng/mL hydrocortisone, and 1% penicillin and streptomycin. Cell lines were verified by multiple methods, including DNA bar coding, gene expression, and transcriptome analysis, and kept in culture for <6 months after receipt.
Cell lysis
Cells were lysed in NP40 lysis buffer [20 mmol/L Tris-HCl (pH 7.0), 10% glycerol, 1% NP40, 10 mmol/L EDTA, 150 mmol/L NaCl, 20 mmol/L NaF, 5 mmol/L sodium pyrophosphate] supplemented with protease inhibitor cocktail (Sigma-Aldrich). Protein concentration was calculated using Bio-Rad Protein Assay solution.
Immunoprecipitation
Equal amounts of protein were incubated at 4°C in a 1-mL volume with 2 μg antibody for 4 hours before addition of protein A-Sepharose beads. Beads were incubated for 2 hours and then washed with 1% NP40 in PBS three times before elution with 2× Laemmli lysis buffer [125 mmol/L Tris (pH 6.8), 23% glycerol, 4% SDS, 10% β-mercaptoethanol, bromphenol blue] and immunoblotting.
Immunoblotting
Cell lysates were equilibrated using the Bio-Rad Protein Assay solution, and protein (50-100 μg) was resolved by SDS-PAGE, transferred to nitrocellulose (Hoefer semidry transfer system, 160 mA, 80-120 minutes), and blocked in 5% nonfat milk in 1% TBST (1% Tween in TBS). Membranes were incubated with the appropriate antibodies (primary antibodies used at the concentration recommended by the manufacturer, ADAM9-S used at 2 μg/mL) for 14 hours. Cell membranes were washed in 1% TBST and incubated with peroxidase-conjugated anti-mouse or anti-rabbit antibodies (Jackson ImmunoResearch) and exposed using highsensitivity enhanced chemiluminescence (Millipore).
Lentiviral infection
pLKO.1 plasmid constructs were cotransfected into HEK293T cells with packaging vectors pCMV-dR8.2 dvpr and pCMV-VSVG using polyethyleimine. Forty-eight hours after transfection, lentiviral particles in supernatant were harvested, passed through a 0.45-μm filter, and either stored at −80°C or used to infect target cells. Target cells at ∼80% confluency were infected with virus alone for a period of 4 hours, at which point they were supplemented with full serum and allowed to recover for 24 hours before selection in puromycin in full culture medium for 18 hours (2-5 μg/mL). 
Transfection of plasmid DNA
Plasmids of interest and the pCS2-(n)-β-galactosidase reporter plasmid were cotransfected at a ratio of 6.5:1 into noninfected or lentivirally infected cells 24 hours after infection with Lipofectamine 2000 according to the manufacturers' instructions. Medium was replaced with full culture medium for noninfected cells or puromycin selection medium 4 hours after transfection. Cells were assayed for migration and protein expression 24 hours after transfection.
Migration assays
Migration assays were carried out using Transwell chambers (Corning) with 8-μm pore membranes. Cells were trypsinized and resuspended in serum-free medium containing 0.1% bovine serum albumin (BSA). Cells (1 × 10 5 ) were added to the top of each Transwell chamber and allowed to migrate toward cell-conditioned medium for 4 to 16 hours at 37°C depending on the cell type. Cells that had migrated to the lower surface of the membrane were fixed and stained. Lentivirally infected cells were stained with Hema-3 Protocol Stain (Fisher Scientific). Cells cotransfected with expression plasmids and β-galactosidase were stained with X-galactosidase. Experiments were conducted in triplicate, and equal fields of stained cells were counted in each well and normalized to the plating efficiency or the transfection efficiency. Transfection efficiency was calculated by counting the number of transfected cells per 100,000. Plating efficiency was calculated by counting two wells of 100,000 cells plated in parallel to the migration assays to control for minor discrepancies in plating. Statistical analysis was performed using ANOVA and the InStat statistical analysis software. Cell-conditioned medium was harvested from NIH3T3 fibroblast cells grown in full serum for 48 hours to confluency, or HEK293T cells transfected with hADAM9-S expression plasmids, and incubated in serum-free medium for 48 hours.
Integrin-blocking assays
Cells were infected and transfected with plasmid DNA as described above. Before migration assay, cells were trypsinized and incubated with 5 μg/mL of GOH3 antibody for 10 minutes at room temperature.
Results
ADAM9-S is expressed in breast cancer cell lines and breast tumors
We first determined the expression pattern of ADAM9-S and ADAM9-L in breast cancer cells and breast cancer tissues. To detect specific endogenous isoforms of ADAM9, a polyclonal antibody directed toward the COOH terminus of ADAM9-L and an ADAM9-S-specific polyclonal antibody designed against the unique COOH terminus of human ADAM9-S were used (Fig. 1A) . To confirm isoform specificity, COOH-terminal myc-tagged murine ADAM9-L and human ADAM9-S were transiently expressed in HEK-293T cells. Equal amounts of protein were immunoblotted with myc antibody to validate equivalent expression and ADAM9 antibody specificity. The results show that, as expected, ADAM9-L is detected by myc and ADAM9-L antibodies as a pro-ADAM9-L variant that comprises the unprocessed form migrating at 114 kDa and the fully processed mature membrane-bound form at 84 kDa (Fig. 1B) . Expression of ADAM9-S is detected by myc and ADAM9-S antibodies at 67 kDa, as previously shown (26) . Importantly, the ADAM9-L antibody does not cross-react with ADAM9-S, and the ADAM9-S antibody does not detect ADAM9-L (Fig. 1B) . Therefore, specific antibodies against ADAM9-L and ADAM9-S are specific to the secreted and membrane-bound variants of ADAM9. It is important to note that ADAM9-L and ADAM9-S migrate slower on SDS-PAGE than their predicted molecular mass due to the presence of cysteine-rich regions as well as glycosylation.
To evaluate the expression of ADAM9-S and ADAM9-L in breast cancer cell lines, lysates were collected from BT549, HCC38, MDA-MB-231, SUM159PT, MCF10A, MDA-MB-468, CAMA-1, ZR75-1, MCF-7, and SKBR3 cells at approximately 80% to 90% confluence, and ADAM9 expression was determined by immunoblotting. ADAM9-L expression is detected in all cell lines tested (Fig. 1C, dark exposure) . Importantly, cells previously characterized to overexpress ADAM9 (BT549, HCC38, and CAMA-1; ref. 31) reveal a substantially higher level of expression of ADAM9-L compared with other lines (Fig. 1C,  light exposure) . In addition, the variance in ADAM9-L bands detected by immunoblotting reflects differences in processing as well as posttranslational modifications that include proteolytic cleavage and glycosylation. ADAM9-S endogenous expression is detected in BT549, HCC38, SUM159PT, MCF10A, and MDA-MB-468 cells (Fig. 1C) . Thus, endogenous ADAM9-L expression is detected in cells of both the luminal and basal breast cancer subtypes, whereas ADAM9-S is predominantly observed in basal-type cells. Notably, CAMA-1, a noninvasive cell type, expresses ADAM9-L, but not ADAM9-S.
To evaluate expression of ADAM9 isoforms in breast cancer tissues, ADAM9-S levels were evaluated in stage II and III invasive ductal carcinoma tumor and normal breast lysate samples kindly provided by Dr. Gerburg Wulf (Beth Israel Deaconess Medical Center; ref. 34 ). The results show that ADAM9-S is expressed in breast cancers of both grades as well as in normal tissue (Fig. 1D) .
Overexpression of ADAM9-S promotes breast cancer cell migration
Previous studies have shown that cancer cells exhibit increased translocation through Matrigel in the presence of exogenous recombinant ADAM9-S (26). To evaluate the role of ADAM9 isoforms in cell migration independent of matrix proteolysis, motility was assayed using uncoated Transwells. Plasmid constructs directing the expression of wild-type and mutant murine ADAM9-L and human ADAM9-S ( Fig. 2A ) Figure 1 . Expression of ADAM9 isoforms in breast cancer cell lines and tissues. A, a schematic representation of the membrane-bound (ADAM9-L) and secreted (ADAM9-S) isoforms of ADAM9. B, HEK293T cells transiently transfected with a vector control (pcDNA4), murine ADAM9L.myc, and human ADAM9S.myc were lysed and proteins were resolved on an 8% SDS-PAGE gel. Equivalent lanes were blotted with anti-myc to validate protein expression. Equivalent lanes were blotted with ADAM9-L-and ADAM9-S-specific antibodies. C, a panel of cell lines representing breast cancer subtypes was used for immunoblotting with ADAM9-L COOH-terminal-specific antibody, ADAM9-S COOH-terminal-specific antibody, and β-actin. "#" denotes overexpression of ADAM9 and amplified 8p11-12; "*" denotes amplified 8p11.12. D, SDS-extracted lysates from frozen tumor blocks were immunoblotted with anti-ADAM9-S antibody. BT549 cell lysate was used as control. All results are representative of at least three independent experiments.
were transfected into BT549 breast cancer cells. Overexpression of wild-type ADAM9-S significantly increases BT549 migration. In contrast, overexpression of a metalloproteinase-deficient ADAM9-S.EA mutant with a Glu to Ala substitution in the metalloproteinase active site (35) does not increase migration and is comparable with controltransfected cells (Fig. 2B) . Similarly, overexpression of the ADAM9-L variant did not promote BT549 cell migration, nor did overexpression of the equivalent metalloproteinasedeficient ADAM9L.EA mutant. Therefore, as previously reported, ADAM9-S promotes cell migration in a protease activity-dependent manner. However, this phenotype is not recapitulated by ADAM9-L.
To confirm that extracellular ADAM9-S stimulates cell migration, ADAM9-S, ADAM9S.EA, or vector control was expressed in HEK293T cells and serum-free conditioned medium was collected after transfection. These supernatants were added to the bottom chamber of uncoated Transwells, and BT549 breast cancer cells were added to the top chamber. Under these conditions, BT549 cells require an extended 16-hour incubation period to migrate. However, BT549 cells exhibit increased migration when exposed to ADAM9-S-containing conditioned medium in comparison with control-transfected or ADAM9S.EA-transfected medium, indicating that exogenous ADAM9-S stimulates haptotactic migration through its metalloproteinase activity (Fig. 2C) .
ADAM9 silencing increases breast cancer cell migration
To determine the functional role of endogenous ADAM9 in cell migration, we performed loss-of-function experiments using a siRNA oligonucleotide pool targeting five distinct sequences spanning both ADAM9 isoforms. We chose to transiently transfect these siRNAs into BT549 cells, which express high levels of ADAM9 and are also highly migratory. Surprisingly, ADAM9 siRNA increases migration in BT549 cells as measured by Transwell migration assays compared with control or nontarget siRNA (Fig. 3A) . This is concomitant with quantitative silencing of ADAM9-L protein expression. The phenotype of increased migration by ADAM9 siRNA recapitulates that observed on expression of ADAM9-S (Fig. 2A) . To evaluate that this is not due to an off-target effect of the siRNA pool, two distinct lentiviral shRNA constructs were generated to target both isoforms in the 3′ untranslated region of ADAM9 mRNA (ADAM9shRNA.1) and the cysteinerich domain (ADAM9shRNA.2). After lentiviral infection and selection, robust silencing of ADAM9-L and ADAM9-S Figure 3 . ADAM9 silencing increases cell migration. A, BT549 cells were transfected with β-galactosidase alone, or in conjunction with nontargeting siRNA oligonucleotide, or ADAM9 siRNA oligonucleotide pool. Cells were migrated for 16 h. *, P < 0.01, ANOVA. Silencing was confirmed by immunoblotting using ADAM9-L COOH-terminal-specific antibody and β-actin. B, BT549 cells infected with ADAM9shRNA.1 and ADAM9shRNA.2 were lysed and immunoblotted against ADAM9-L and ADAM9-S. ADAM9-S was immunoprecipitated from equal cell lysates before immunoblotting. C, BT549 cells were infected with control or ADAM9shRNA.1 lentiviruses before transfection of pcDNA control, ADAM9-L, ADAM9-S, and ADAM9S.EA. Cells were migrated for 4 h. *, P < 0.05; **, P < 0.001, ANOVA. ADAM9-L immunoblot confirms silencing. ADAM9-S expression is detected with anti-myc.
protein is observed in cells transduced with both sequences as revealed by immunoblotting (Fig. 3B) . Importantly, transduction of both shRNA sequences also results in an increase in BT549 cell migration (Fig. 3D) . Moreover, increased cell migration resulting from transduction of ADAM9 shRNA is also reproduced in distinct breast cancer cell lines, including CAMA-1 and ZR75-1 (Fig. 3D) . Therefore, in different luminal and basal breast cancer type cells, silencing ADAM9 expression results in enhanced cell migration observed with ADAM9shRNA.1 and ADAM9shRNA.2 sequences.
To further confirm that ADAM9 silencing is responsible for the increase in migration observed with shRNA, a reconstitution experiment was performed by introducing murine ADAM9-L and human ADAM9-S in cells harboring ADAM9
shRNA. The murine ADAM9-L (mADAM9-L) would be predicted to be refractory to silencing using human ADAM9. Consistent with this, expression of mADAM9-L protein was resistant to silencing in cells expressing ADAM9 shRNA compared with cells with ADAM9 shRNA alone that show a robust reduction of ADAM9-L protein (Fig. 3C) . In Transwell assays, expression of mADAM9-L rescues the increase in migration observed with shRNA alone. Therefore, the increase in migration observed on silencing of ADAM9 is specific to ADAM9-L expression and is not due to off-target effects. The implication is that endogenous ADAM9-L is a suppressor of migration of breast cancer cells.
We also evaluated the contribution of ADAM9-S in the enhanced migration phenotype observed with ADAM9 shRNA. As observed in Fig. 2A , expression of wild-type, but not protease-deficient, ADAM9-S increases cell migration in control BT549 cells (Fig. 3C) . In contrast to the effect of expression of mADAM9-L, the increase in migration induced by ADAM9 silencing is not rescued by expression of ADAM9-S that is refractory to silencing, as the shRNA used (ADAM9shRNA.1) targets the 3′ untranslated region. Instead, expression of ADAM9-S leads to a further increase in the migratory phenotype that is additive to ADAM9 shRNA and ADAM9-S. As expected, this additive effect is not recapitulated by expression of the ADAM9-S protease-inactive EA mutant (Fig. 3C) . Therefore, ADAM9-S does not phenocopy the migration suppression function of ADAM9-L, and moreover, the implication from these results is that suppression of migration is the dominant role of ADAM9 in breast cancer cells.
Functional role of ADAM9-L domains in suppression of cell migration
The data thus far show that ADAM9-S is an enhancer of cell migration, whereas ADAM9-L is a suppressor of migration. We next determined the contribution of the ADAM9-L functional domains in the suppression of migration. We generated mutations or deletions in the metalloproteinase (ADAM9L.EA), disintegrin (ADAM9L.Δdis), and cytoplasmic (ADAM9L.Δcyt) domains (Fig. 4A) . Again the murine ADAM9-L allele was used to generate these mutations, as it is refractory to silencing in human breast cancer cells. Wild-type and mutant mADAM9-L alleles were introduced into BT549 cells after silencing with ADAM9 shRNA. As already observed, expression of the wildtype ADAM9-L allele rescued the phenotype of increased migration on ADAM9 silencing (Fig. 4B) . This was also observed in cells expressing the metalloproteinase-deficient ADAM9L.EA mutant, indicating that the proteolytic activity of ADAM9-L is dispensable for the suppression of migration. In contrast, there was no rescue of increased migration with the cytoplasmic domain deletion mutant (ADAM9L.Δcyt), showing that localization and downstream signaling mediated by the ADAM9-L cytoplasmic domain is required for suppression of cell migration (Fig. 4C) .
To address the role of the ADAM9-L disintegrin domain and integrin-binding activity, point mutations in the ECD motif as well as whole deletions in the integrin-binding domain were generated. However, expression of these mutant proteins followed by immunoblotting revealed that both mutants are not properly processed from the prodomaincontaining form (114 kDa) to the active and mature 84-kDa form compared with wild-type ADAM9-L (Fig. 5A) . Therefore, we assessed the contribution of the disintegrin domain in the regulation of cell migration using integrin function-blocking antibodies. BT549 cells were transduced with ADAM9 shRNA and reconstituted with wild-type murine ADAM9-L, followed by treatment with GOH3, an antibody that blocks α 6 integrin binding to its ligand laminin (Fig. 5B) , or control IgG. GOH3 is also routinely used as direct binding ligand to activate integrin clustering (36) . Interestingly, treatment with GOH3 modestly increased the migration of BT549 cells with control pLKO. As predicted by the data thus far, silencing ADAM9 with shRNA increased cell migration compared with control 
Discussion
The ADAM family of metalloproteinases controls multiple phenotypes associated with tumor progression, although the specific role of individual isoforms in tumorigenesis is poorly understood. Several ADAM isoforms, including ADAM9, have been shown to promote cell migration. In this study, we identify nonredundant roles for the secreted and membrane-bound ADAM9 variants in breast cancer cell migration. Consistent with previous observations, we show that ADAM9-S can promote breast cancer cell migration in a cell-autonomous manner. Surprisingly, this phenotype is not recapitulated by ADAM9-L, which functions as a migration suppressor.
The ADAM9 gene (8p11.23) is located in the 8p11-12 cluster that is frequently amplified or deleted in breast cancer, with instances of abnormal copy number that correlate with reduced patient survival (37) . Although ADAM9-null mice have no overt phenotypes (38) , in mouse models of breast, colon, and prostate carcinoma such as MMTV-PyMT, APC/Min/+, and W
10
, overexpression of ADAM9 in neoplastic regions is detected (35) . ADAM9
−/− W 10 mice have well-differentiated tumors compared with tumors in ADAM9 +/+ W 10 (35) . Immunohistochemical analysis of ADAM9 expression in breast tumors and cell lines supports our finding that secreted ADAM9-S is expressed in breast cancer tissues (29, 30) . In our studies, the ADAM9-specific antibodies were unable to provide a clear detection of protein expression by immunohistochemistry or immunocytochemistry, but regardless, this is the first clear identification of ADAM9-S expression in tumors and cell lines.
Breast cancer cell lines are separated into different clusters based on gene expression profiles (39) . Luminal cell lines express genes associated with a more differentiated, noninvasive phenotype, whereas basal cell lines are less differentiated and more invasive. In a survey of gene expression profiles of 51 breast cancer cell lines, the basal gene cluster was separated into two groups, basal A and B, of which B has a stem cell-like expression profile closest to the clinical "triple-negative" tumor profile (31) . Cell lines with ADAM9 amplification and with or without ADAM9 mRNA overexpression were identified in this analysis. In our present study, we find that ADAM9-L is expressed in cells of each gene cluster, whereas ADAM9-S is expressed primarily in the more aggressive basal genotype (Fig. 1C) , correlating with the finding that ADAM9-S promotes cell migration.
Our previous studies had identified ADAM9-S as a promigration factor that is secreted by activated liver myofibroblasts in the wound-healing response (26) . Tumors are sites of chronic wounding, and cancer cells adapt to the wound by increasing cell migration and angiogenesis. The success of tamoxifen treatment in recurrent breast cancer with a high stromal content is correlated with elevated levels of ADAM9 (40) . Similarly, ADAM9 is upregulated in the stroma surrounding invasive melanoma (41) and colon cancer (26) , as well as prostate cancer cells (42, 43) . These studies emphasize the importance of ADAM9 function at the tumor-stromal boundary, suggesting that ADAM9 may function downstream of paracrine factors involved in wound healing. We find that whereas ADAM9-S promotes cell migration via its metalloproteinase activity ( Fig. 2A) , ADAM9-L functions as a migration suppressor in a manner that is independent of proteolytic activity (Fig. 4B ). ADAM9-S may proteolyze specific substrates on the cell surface or ECM that are not targeted by ADAM9-L, as its localization is restricted by membrane tethering. Consistent with this, cells expressing ADAM9-S have a higher rate of migration than cells exposed to a more diffuse exogenously Figure 4 . ADAM9-L suppresses cell migration in a metalloproteinaseindependent manner. A, schematic representation of murine wild-type ADAM9 isoforms and functional domain mutations used to assess the role of each domain in cell migration. B, BT549 cells were infected with control or A9shRNA.1 lentiviruses before transfection with pcDNA control, mADAM9-L wild-type, or mADAM9L.EA after selection. Cells were migrated in uncoated Transwells for 4 h. *, P < 0.01, ANOVA. Cell lysates were immunoblotted against actin and ADAM9-L to detect both murine (top arrows) and human (bottom arrows) variants. C, BT549 cells were infected with control or A9shRNA.1 lentiviruses before transfection with pcDNA control, mADAM9-L wild-type, or mADAM9L.Δcyt after selection. Cells were migrated in uncoated Transwells for 4 h. *, P < 0.05; *** P < 0.001, ANOVA. ADAM9-L expression is detected with anti-myc, ADAM9 silencing is detected with anti-ADAM9-L, and actin is control. ns, nonspecific immunoreactive protein. In all experiments, cell counts were normalized to transfection efficiency. Columns, mean of triplicate measurements of at least three independent experiments; bars, SD. added ADAM9-S ( Fig. 2A and B) , indicating that ADAM9-S might function in a cancer cell-autonomous manner rather than acting on the tumor stroma. Regardless, the opposing functions of ADAM9-L and ADAM9-S in cell migration suggest that the two splice variants control tissue homeostasis, with isoform-specific functions in response to signals from both neighboring tumor and stromal cells. A recent shRNA screen for cell migration enhancers and suppressors identified ADAM9 as a migration suppressor in nontumorigenic MCF10A epithelial cells, consistent with our findings (44) . Surprisingly, we find that the ADAM9-L metalloproteinase domain is dispensable for this phenotype, whereas the cytoplasmic and disintegrin domains are required, indicative of a role for membrane localization and cytoplasmic signaling.
The disintegrin domain of ADAM9 influences cell migration in a cell type-dependent manner. Keratinocytes adhering to recombinant ADAM9-L disintegrin domain exhibit increased migration (25) , a result also observed with fibroblasts adhering to recombinant ectodomain (45) . In contrast, recombinant disintegrin domain inhibits the adhesion of platelets to collagen I (46) and interacts with multiple integrins, resulting in extracellular signal-regulated kinase phosphorylation, activation of p38MAPK, cPLA 2 , and MMP-9 synthesis (25, 27) . In breast carcinoma cells, antibody binding to α 6 integrin enhances migration, a phenotype that is significantly enhanced in the absence of ADAM9 expression (Fig. 5B ). ADAM9-L may control the localization of integrins or syndecans to specific lipid rafts (47) , or alternatively modulate endocytosis of cell surface receptors. ADAM9 has also been shown to interact with and promote the recycling of E-cadherin in colon cancer cells, and this may represent a metalloproteinase-independent mechanism for ADAM9-L (48).
The opposing roles for ADAM9-S and ADAM9-L as migration enhancers and suppressors in breast cancer cells raise the question as to how the expression profile of each splice variant is regulated. This is predicted to have a major effect in tumor progression, as cells overexpressing ADAM9-L would presumably have a reduced migration phenotype. Conversely, any tumors in which ADAM9-S is the predominant isoform would be predicted to have aggressive invasive and metastatic characteristics. Although presently unknown, it is highly likely that one important mechanism is the control of alternative splicing of the ADAM9 message.
In summary, our results show that the secreted and membrane-tethered isoforms of ADAM9 have opposing Figure 5 . The ADAM9-L integrinbinding activity modulates cell migration. A, HEK293T cells were transfected with wild-type mADAM9-L, point mutant mADAM9L.TCE.myc, and mADAM9.Δdis.myc. Lysates were immunoblotted with ADAM9-L COOH-terminal antibody. B, BT549 cells infected with control pLKO or ADAM9shRNA.1 virus were transfected with pcDNA control or mADAM9-L wild-type constructs. Cells were resuspended in 0.01% BSA in PBS with 5 μg/mL GOH3 antibody and incubated for 10 min before a 4-h migration assay. Lysates were immunoblotted with ADAM9-L COOH-terminal antibody to confirm silencing and expression. Columns, mean of triplicate measurements of two independent experiments; bars, SD. P values were calculated using ANOVA. *, P < 0.05; ***, P < 0.001.
functions in breast cancer cell migration. The expression of both isoforms in breast cancer tumors and stroma suggests a model in which the secreted ADAM9-S acts as a migratory stimulant, whereas ADAM9-L tethered to the plasma membrane binds cell surface proteins and mediates localization and signaling. One important implication from these findings is that isoform-specific functions of secreted and membranetethered proteases exist, which has obvious consequences for the development of small-molecule inhibitors for therapeutic intervention.
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